Novo Nordisk stock extends buyback as trial updates and obesity growth shape outlook

Published on 09/09/2026 at 14:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo Nordisk stock trades well below recent highs as of September 8, 2026, while the company continues a DKK 15 billion share repurchase and reports 20% obesity care sales growth in the first half of 2026. The latest clinical and obesity data highlight both pipeline risk and demand momentum for investors.

Flatlay mit Spritze, Teststreifen, Notizbuch und Apfel auf weißem Untergrund — Novo Nordisk A/S (DK0062498333): Flatlay mit Spritze, Blutzucker-Teststreifen, Notizbuch und Apfel auf Weiß, Illustration mit AI erstellt.

Novo Nordisk stock (ISIN DK0062498333) is trading significantly below its recent peak, with its New York Stock Exchange ADR changing hands at around USD 45 in early September 2026, compared with a 52-week high of USD 64.16 and a low of USD 35.12 as of September 8, 2026, according to data cited by GuruFocus.

Share repurchase programme underpins Novo Nordisk stock

According to Globenewswire on September 7, 2026, Novo Nordisk has been executing a share repurchase programme of up to DKK 15 billion over the 12-month period beginning February 4, 2026, signalling ongoing capital returns to shareholders.

Under the programme initiated on May 6, 2026, the company plans to repurchase B shares for up to DKK 11,200,000,010.45 between May 6, 2026 and February 1, 2027, illustrating the scale of the buyback commitment over the current financial year, according to Globenewswire.

The same announcement shows that, from February 4, 2026 through September 4, 2026, Novo Nordisk had already repurchased a total of 32,034,179 B shares at an average price of DKK 281.63 per share, equivalent to a transaction value of DKK 9,021,774,283, illustrating that roughly 60.1 percent of the intended DKK 15 billion buyback volume had been deployed by early September 2026, per Globenewswire.

Obesity care growth and semaglutide data support fundamentals

Beyond capital returns, Novo Nordisk continues to report robust demand in obesity care, with total reported Obesity care sales increasing 20 percent year over year in the first half of 2026 in Danish kroner, or 24 percent at constant exchange rates, driven primarily by higher sales across the Wegovy portfolio including incremental revenue from the newly launched Wegovy pill, according to Zacks Investment Research.

As Zacks Investment Research reports, Novo Nordisk recently disclosed top-line results from the phase III STEP Young study in pediatric obesity, showing that 40.4 percent of children treated with once-weekly subcutaneous semaglutide were no longer classified as having obesity after 68 weeks, compared with none in the placebo group, highlighting significant efficacy in a difficult-to-treat population.

Per the same STEP Young study summary, two out of five children receiving semaglutide reduced their body mass index below the obesity threshold into either normal-weight or overweight classifications, again versus none on placebo, while the overall safety and tolerability profile was consistent with prior pediatric and adult trials and revealed no new safety concerns, according to Zacks Investment Research.

Pipeline setbacks and guidance context for Novo Nordisk stock

A recent article highlights that Novo Nordisk has faced a mixed picture across its late-stage pipeline, with two cardiovascular trials of the anti-inflammatory antibody ziltivekimab in heart failure patients terminated early after an independent data monitoring committee concluded they were unlikely to deliver materially different results from a prior investigation that had already failed, while another ziltivekimab study in post-heart-attack patients continues with data expected in the first half of 2027, as reported on September 9, 2026 by Ad-hoc-news.

Despite the pipeline impairment related to ziltivekimab, Novo Nordisk reaffirmed its guidance for adjusted operating profit for 2026 and flagged that the impairment would be a non-cash charge in the third quarter of 2026, indicating that the setback is expected to affect accounting results but not the company’s cash generation outlook, per Ad-hoc-news.

The same report notes that Novo Nordisk stock, quoted in euros on a secondary European venue, has fallen about 30 percent from a 52-week high of EUR 54.86 in late January 2026 to EUR 38.56 in early September 2026, and is down more than 6 percent over the past month, illustrating the magnitude of the correction relative to previous levels, according to Ad-hoc-news.

Valuation signals and market positioning

On the valuation side, Novo Nordisk’s ADR currently trades at around USD 45.16 as of September 8, 2026, which one analysis describes as approximately 58.3 percent below a GF Value estimate of USD 108.37, suggesting that the shares change hands at a significant discount to an intrinsic value model, according to GuruFocus.

The same analysis shows that, over the past 52 weeks, the ADR price fluctuated between a high of USD 64.16 and a low of USD 35.12, so the current level near USD 45.16 places the stock roughly 29.6 percent below the high and about 28.6 percent above the low, giving investors a sense of where the shares sit within their recent trading range, per GuruFocus.

Novo Nordisk stock price as of the latest trading day

As of September 8, 2026, Novo Nordisk’s American depositary receipts on the New York Stock Exchange closed at about USD 45.16, with the prior close and intraday move reflecting a roughly 3.1 percent decline on the day versus the previous session, while the market capitalization and volume at that time were consistent with the company’s status as a large-cap global healthcare group in the obesity and diabetes space.